We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Scancell Holdings Plc | LSE:SCLP | London | Ordinary Share | GB00B63D3314 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.10 | -1.03% | 9.65 | 9.30 | 10.00 | 9.75 | 9.65 | 9.75 | 542,863 | 10:14:22 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 5.27M | -11.94M | -0.0129 | -7.48 | 89.53M |
Date | Subject | Author | Discuss |
---|---|---|---|
21/9/2023 12:02 | by the way Ruck why did you not answer it ... instead of copy pasting other peoples work | inanaco | |
21/9/2023 11:58 | the key to modi1 ..... what is arresting those t cells .......... then add checkpoints to suit .... it is highly complex .......... but can be explained simply ..... but you need the Target and the right T cells .............. moditope gives you targets across all solid cancers | inanaco | |
21/9/2023 11:51 | ruck ray and bermuda did not answer the question ""There may have been some confusion between the two and what they are supposed to do."" | inanaco | |
21/9/2023 11:48 | its far more complex than just the difference between hcit and cit because hcit is far more active on cancer cells that expand in the cancer the very dangerous ones because they suppress the immune system "myeloid-derived suppressor cells" What are myeloid-derived suppressor cells in cancer? Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of cells of myeloid origin. MDSCs expand during various pathological conditions, including cancer, inflammation and trauma, and are characterized by the increased production of reactive oxygen and nitrogen species, and by arginase its also the way the CD4 killer t cells negotiate with cd4 suppressor cells which is what this coming poster is about and this is why its possible to add modi2 to modi1 scancell will crack the best way forward for sure we have the assets just remember the main attack for all immunotherapy comes from the T cells whats missing is the Target for those T cells the way they are activated the phenotype ie th1 the Avidity ....... ability to bind then other elements need to be added to help control the cancers ability to cloak itself so the more defense you knock out with Checkpoint inhibitors.......... the better the attack both scib1 and moditope work .. because your using checkpoints this also invigorates other immune effector cells the second attack line .......... add modi2 and you get a specific attack line against another suppressor cell "all combined force movement" | inanaco | |
21/9/2023 11:42 | So Inanco according to you the posters are about to be presented in 4 minutes. | octopus100 | |
21/9/2023 11:38 | And Ray........ Just to add a little more detail to Berm's reply. Proteins comprise chains of amino acids. The two simplest amino acids are arginine and lysine. Modi1 targets a change to arginine call citrullination. Similarly, Modi2 targets a change to lysine called h o m o citrullination. Both changes are classed as Stress Induced Post Translational Modifications (SIPTMs). The changes can occur on different proteins and at different positions in the proteins. This means that both Modi1 and Modi2 can target different occurrences of the changed amino acids (arginine for Modi1 and lysine for Modi1). Lindy has also expressed excitement at being able to combine Modi1 and Modi2 which is obviously a few years off. This excitement tends to indicate that some cancers exhibit both citrullination (Modi1) and h o m o citrullination (Modi2). | ruckrover | |
21/9/2023 11:24 | krafty1305 Posts: 2,318 Price: 17.00 No Opinion ModitopeToday 07:19 I wonder if someone can help me. Some discussion on what moditope can do based on trial results so far. What we have had is a trial of moditope 1 on the hardest to treat cancers building up the dose level and evolving now to a combo trial. Today's poster is on moditope 2 and its effect on solid tumours. The excitement around Moditope has always been it will make the solid tumours melt away. Now to my lay/autistic brain that sounds like moditope 2. So can someone please explain to me the difference between moditope 1 and 2. There may have been some confusion between the two and what they are supposed to do. IE: moditope 1 was never going to do what moditope 2 can. IE they are different, do different things and so on and are for different types of patients. Any help explaining I would be most grateful | inanaco | |
21/9/2023 11:11 | I see the Wisdom Of Loz ... selling at the top of the market ...just heading into winter cant see that happening very quickly ... ATB Loz Fun while it lasted | inanaco | |
21/9/2023 10:56 | Lozan, I hope all goes well for you and you find a place in the UK that will give you as much pleasure as the French pad. BTW, I think GF could be interested in buying Lozan Towers - he's obviously obsessed with your lifestyle and stock of logs. | ruckrover | |
21/9/2023 10:36 | Pharmajet is better than electroporation Topline results of the analysis showed that DNA vaccines delivered needle-free tend to induce immunogenicity that is non-inferior to electroporation. DNA vaccines delivered needle-free also tend to elicit improved immunogenicity compared with N/S, according to the authors of the publication. In addition, compared with electroporation and with N/S, needle-free PDS provide a wider dispersion pattern of the DNA vaccine within tissues and more precise, efficient delivery into cells.1 More attractive to big pharma in comparison to the hassle of administration by electroporation | marcusl2 | |
21/9/2023 10:25 | Thought for the day What if the Melanoma patients had been on a forum. 94% for me 80% here and still shrinking. Sentiment and the associated irrational behaviour caused largely unjustified price swings. | chilltime | |
21/9/2023 10:11 | Those were my thoughts exactly during question time. The tone of LD's replies was like "do I really have to engage with these idiots?" I didn't get the same feeling and indeed apart from the one silly question I thought the rest were good ones and Lindy even commented on everyone (except the silly one) with "that's a good question" so that kind of blows your point out of the water. | nigelpm | |
21/9/2023 10:07 | Lozan, Yes, a huge decision to make but you've had some very happy years and banked some wonderful memories. Am sure the future holds many more back in the UK and wish you all the very best with the move. | bermudashorts | |
21/9/2023 10:03 | chilltime, Those were my thoughts exactly during question time. The tone of LD's replies was like "do I really have to engage with these idiots?" | ruckrover | |
21/9/2023 09:55 | I wish you well Lozan - that must have been a big decision for you both to leave Loz Towers, which admittedly, sounded lovely over the years. Good luck with it all. | torquayfan | |
21/9/2023 09:51 | Time to get busy on the filter button, exciting times ahead. My Dad is bigger than your Dad was beyond excessively boring long ago. On the poster front, clearly data from pre clinical models which must be very good. I look forward to reading that. | chilltime | |
21/9/2023 09:46 | Morning Lozan, Thank you for your contributions over the Years and hope your move goes well. | ivyspivey | |
21/9/2023 09:46 | Institutions That news, the way it was written, then the live meet with broker analyst questions was a complete step change to the past. All too often as private high stakes investors we anticipate x,y or z will excite big industry and surely become a blockbuster. The beauty of this sector is if you find the magic mix, to beat the standard of care by the required margin, it’s not a case of IF but when. The institutions by in, the dabbling trader/holders shares are gobbled up. Scancell has been largely ignored other than by Redmile and Vulpes. The analyst questions, summed up that point. “Do you inject into THE tumour” The answer should have been “No you blithering idiot it’s a shot in the arm vaccine” Then Is the injection method approved🤦 Answer “Yes you complete tit, do you actually read the news, or have the slightest clue about Scancell, it’s easier to deliver than a typical injection, with no needle fear involved” The analysts will be excited as will Bristol Myers. | chilltime | |
21/9/2023 09:44 | I second this request Marcus tends to post every post 4 times at least | golcheja | |
21/9/2023 09:43 | Hope the move goes well. | markingtime | |
21/9/2023 09:29 | It is not my intention to upset - I appear to be the focus of much attention today, causing EGOb to post 16 times before sun-up. I have decided to quit posting my views on the *LIEZARUS* forum. Indeed, in these 'troubled times' worldwide, Mrs Lozan and I have chosen to 'move back to U K', having today placed Lozan Towers on the market. It was good while it lasted. | the real lozan | |
21/9/2023 09:18 | I would prefer that only posts about the science are put up but that is not going to happen. | marcusl2 | |
21/9/2023 09:16 | In my view it just adds to the mess and makes it harder to navigate - it's a polite request - I can't stop you posting. Your call. | nigelpm |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions